IceCure Medical Sees Demand for ProSense Systems Accelerate in 2026
ByAinvest
Wednesday, Nov 19, 2025 9:04 am ET1min read
ICCM--
• FDA grants marketing authorization for ProSense cryoablation system. • Local cryoablation treatment for low-risk breast cancer. • Demand expected to accelerate in 2026. • Total US population of approximately 200,000 patients. • Women aged 70+, not suitable for surgery and benign breast tumors. • Company to hold conference call on November 19, 2025. • IceCure Medical Ltd. reports financial results for nine months ended September 30, 2025. • ProSense cryoablation system destroys tumors by freezing.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet